Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 2/2012

01-02-2012 | Original article

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma

Authors: Mizue Terai, Masumi Eto, Garbo D. Young, David Berd, Michael J. Mastrangelo, Yutaka Tamura, Kenichi Harigaya, Takami Sato

Published in: Cancer Immunology, Immunotherapy | Issue 2/2012

Login to get access

Abstract

We previously reported that substantial amounts of IL-10, an immunomodulatory cytokine, are produced by cell suspensions of fresh human metastatic melanoma tissues. Production diminished with continuous culturing of cells, which suggests a pivotal interactive role between melanoma cells and the tumor microenvironment. In this study, we found that the culture media obtained from LPS-stimulated peripheral blood mononuclear cells induced IL-10 production by metastatic melanoma cells. Of the multiple cytokines present in the conditioned culture media, IL-6 was identified as the inducer of IL-10 production. A neutralizing antibody against IL-6 completely blocked the conditioned medium-induced IL-10 production. Metastatic melanoma cells that constitutively produce low amount of IL-10 increased IL-10 production in response to recombinant human IL-6 in a dose-dependent fashion. The response to exogenously added IL-6 was less significant in melanoma cells that produced high amounts of IL-6, probably due to pre-existing autocrine stimulation of IL-10 by endogenous IL-6. On the other hand, metastatic melanoma cells that do not constitutively produce IL-10 protein did not respond to exogenous IL-6. In IL-6-responsive melanoma cells, IL-6 increased STAT3 phosphorylation and inhibition of STAT3 signaling using siRNA or inhibitors for JAKs diminished IL-6-induced IL-10 production. In addition, inhibition of MEK and PI3K, but not mTOR, interfered with IL-10 production. Taken together, the data suggest that blocking of these signals leading to IL-10 production is a potential strategy to enhance an anti-melanoma immune response in metastatic melanoma.
Literature
1.
go back to reference Colombo MP, Mantovani A (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65:9113–9116PubMedCrossRef Colombo MP, Mantovani A (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65:9113–9116PubMedCrossRef
2.
go back to reference Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRef Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRef
3.
go back to reference Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedCrossRef Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedCrossRef
4.
go back to reference Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef
5.
go back to reference Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979PubMedCrossRef Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979PubMedCrossRef
6.
go back to reference Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151–156PubMedCrossRef Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151–156PubMedCrossRef
7.
go back to reference Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383–1390PubMed Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383–1390PubMed
8.
go back to reference Kim J, Modlin RL, Moy RL et al (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240–2247PubMed Kim J, Modlin RL, Moy RL et al (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240–2247PubMed
9.
go back to reference Ordemann J, Jacobi CA, Braumann C, Schwenk W, Volk HD, Muller JM (2002) Immunomodulatory changes in patients with colorectal cancer. Int J Colorectal Dis 17:37–41PubMedCrossRef Ordemann J, Jacobi CA, Braumann C, Schwenk W, Volk HD, Muller JM (2002) Immunomodulatory changes in patients with colorectal cancer. Int J Colorectal Dis 17:37–41PubMedCrossRef
10.
go back to reference Knoefel B, Nuske K, Steiner T et al (1997) Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 17:95–102PubMedCrossRef Knoefel B, Nuske K, Steiner T et al (1997) Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 17:95–102PubMedCrossRef
11.
go back to reference Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937–941PubMedCrossRef Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937–941PubMedCrossRef
12.
go back to reference Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68PubMedCrossRef Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68PubMedCrossRef
13.
go back to reference Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z, Jonjic N (2008) Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 30:230–239PubMedCrossRef Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z, Jonjic N (2008) Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 30:230–239PubMedCrossRef
14.
go back to reference Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma. Asian Pac J Cancer Prev 10:669–674PubMed Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma. Asian Pac J Cancer Prev 10:669–674PubMed
15.
go back to reference Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–1151PubMedCrossRef Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–1151PubMedCrossRef
16.
go back to reference Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403–415PubMedCrossRef Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403–415PubMedCrossRef
17.
go back to reference Berd D, Maguire HC Jr, Schuchter LM et al (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359–2370PubMed Berd D, Maguire HC Jr, Schuchter LM et al (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359–2370PubMed
18.
go back to reference Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577PubMed Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577PubMed
19.
go back to reference Galizia G, Orditura M, Romano C et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178PubMedCrossRef Galizia G, Orditura M, Romano C et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178PubMedCrossRef
20.
go back to reference Negrier S, Perol D, Menetrier-Caux C et al (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d’Immunotherapie. J Clin Oncol 22:2371–2378PubMedCrossRef Negrier S, Perol D, Menetrier-Caux C et al (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d’Immunotherapie. J Clin Oncol 22:2371–2378PubMedCrossRef
21.
go back to reference Porta C, De Amici M, Quaglini S et al (2008) Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 19:353–358PubMedCrossRef Porta C, De Amici M, Quaglini S et al (2008) Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 19:353–358PubMedCrossRef
22.
go back to reference Mouawad R, Benhammouda A, Rixe O et al (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405–1409PubMed Mouawad R, Benhammouda A, Rixe O et al (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405–1409PubMed
23.
go back to reference Taga T, Hibi M, Hirata Y et al (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581PubMedCrossRef Taga T, Hibi M, Hirata Y et al (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581PubMedCrossRef
24.
go back to reference Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027PubMed Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027PubMed
25.
go back to reference Oh JW, Revel M, Chebath J (1996) A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 8:401–409PubMedCrossRef Oh JW, Revel M, Chebath J (1996) A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 8:401–409PubMedCrossRef
26.
go back to reference Muller-Newen G, Kuster A, Hemmann U et al (1998) Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161:6347–6355PubMed Muller-Newen G, Kuster A, Hemmann U et al (1998) Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161:6347–6355PubMed
27.
go back to reference Winston LA, Hunter T (1995) JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 270:30837–30840PubMedCrossRef Winston LA, Hunter T (1995) JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 270:30837–30840PubMedCrossRef
28.
go back to reference Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819PubMedCrossRef Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819PubMedCrossRef
29.
go back to reference Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20PubMedCrossRef Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20PubMedCrossRef
30.
go back to reference Lucas M, Zhang X, Prasanna V, Mosser DM (2005) ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 175:469–477PubMed Lucas M, Zhang X, Prasanna V, Mosser DM (2005) ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 175:469–477PubMed
31.
go back to reference Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMed Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMed
32.
go back to reference Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867PubMedCrossRef Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867PubMedCrossRef
33.
go back to reference Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR (2004) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24:2923–2931PubMedCrossRef Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR (2004) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24:2923–2931PubMedCrossRef
34.
go back to reference Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656PubMedCrossRef Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656PubMedCrossRef
35.
go back to reference Terai M, Tamura Y, Alexeev V et al (2009) Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother 58:1307–1317PubMedCrossRef Terai M, Tamura Y, Alexeev V et al (2009) Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother 58:1307–1317PubMedCrossRef
Metadata
Title
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
Authors
Mizue Terai
Masumi Eto
Garbo D. Young
David Berd
Michael J. Mastrangelo
Yutaka Tamura
Kenichi Harigaya
Takami Sato
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1084-5

Other articles of this Issue 2/2012

Cancer Immunology, Immunotherapy 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine